References
  1. Flory E, Reinhardt J. European Regulatory Tools for Advanced Therapy Medicinal Products. Transfusion Medicine and Hemotherapy. 2013;40(6):5-5.
  2. Committee for Medicinal Products for Human Use, European Medicines Agency. Alofisel® EPAR Public Assessment Report EMA/CHMP/64055/2018 Corr.1 https://www.ema.europa.eu/en/documents/assessment-report/alofisel-epar-public-assessment-report_en.pdf. Accessed May 13, 2020
  3. Committee for Medicinal Products for Human Use, European Medicines Agency. Yescarta® EPAR Public Assessment Report EMA/481168/2018. https://www.ema.europa.eu/en/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf. Accessed May 13, 2020.
  4. Committee for Medicinal Products for Human Use, European Medicines Agency. Kymriah® EPAR Public Assessment Report EMA/485563/2018. https://www.ema.europa.eu/en/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf. Accessed May 13, 2020.
  5. Committee for Medicinal Products for Human Use, European Medicines Agency. Zynteglo® EPAR Public Assessment Report. EMA/56140/2020/Corr.1 https://www.ema.europa.eu/en/documents/assessment-report/zynteglo-epar-public-assessment-report_en.pdf. Accessed May 13, 2020.
  6. European Commission. Regulation (EC) No 1394/2007. Regulation (EC) No 1394/2007. https://eur-lex.europa.eu/eli/reg/2007/1394/oj. Accessed May 7, 2020.
  7. Commission for Advanced Therapies, European Medicines Agency. Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials EMA/CAT/852602/2018. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy_en.pdf. Accessed May 12, 2020.
  8. Pound P, Ritskes-Hoitinga M. Can prospective systematic reviews of animal studies improve clinical translation? J Transl Med 2020; 18:15.
  9. Schinnerling K, Rosas C, Soto l, Thomas R and Aguillón JC, Humanized Mouse Models of Rheumatoid Arthritis for Studies on Immunopathogenesis and Preclinical Testing of Cell-Based Therapies. Front Immunol 2019; Feb 1910:203.
  10. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ2007; 334:197.
  11. Federal Drug Agency. Preclinical Assessment of Investigational Cellular and Gene Therapy Products FDA-2012-D-1038. https://www.fda.gov/media/87564/download. Accessed May 12, 2020.
  12. Commission for Advanced Therapies, European Medicines Agency. Guideline on human cell-based medicinal products. EMEA/CHMP/410869/2006. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-human-cell-based-medicinal-products_en.pdf. Accessed May 12, 2020.
  13. Reyes B, Coca MI, Codinach M, López-Lucas MD, Del Mazo-Barbara A, Caminal M, Oliver-Vila I, Cabañas V, Lope-Piedrafita S, García-López J, Moraleda JM, Fontecha CG, Vives J. Assessment of biodistribution using mesenchymal stromal cells: Algorithm for study design and challenges in detection methodologies. Cytotherapy 2017; Sep19(9):1060-1069.
  14. Leahy M, Thompson K, Zafar H, Alexandrov S, Foley M, O’Flatharta C, Dockery P. Functional imaging for regenerative medicine. Stem Cell Res Ther 2016; Apr 19;7(1):57.
  15. International Conference on Harmonisation. ICH S1 Guideline on the need for carcinogenicity studies of pharmaceuticals S1A. https://database.ich.org/sites/default/files/S1A%20Guideline.pdf. Accessed May 12, 2020.
  16. World Health Organization Technical Report Series 978 Annex 3 2013. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks (Replacement of Annex 1 of WHO Technical Report Series, No. 878). Appendix 2, Tumourigenicity protocol using athymic nude mice to assess mammalian cells. https://www.who.int/biologicals/vaccines/TRS_978_Annex_3.pdf?ua=1. Accessed May 12, 2020.
  17. Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L,Büscher D, Fibbe W, Foussat A, Kwa M, Lantz O, Mačiulaitis R, Palomäki T, Schneider CK, Sensebé L, Tachdjian G, Tarte K, Tosca L, Salmikangas P. Risk of tumorigenicity in mesenchymal stromal cell–based therapies—Bridging scientific observations and regulatory viewpoints. Cytotherapy 2013; 15(7):753-759.
  18. Kuroda T, Yasuda S, Kusakawa S, Hirata N, Kanda Y, Suzuki K, Takahashi M, Nishikawa S, Kawamata S, Sato Y. Highly Sensitive In vitroMethods for Detection of Residual Undifferentiated Cells in Retinal Pigment Epithelial Cells Derived from Human iPS Cells. PLoS ONE 2012; 7(5):e37342.
  19. Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy-Rathinam M, Tauler J., Bikkavilli R, and Winn R. (2014). The Soft Agar Colony Formation Assay. J Neurosurg 2009; 110(6):1189–1197.
  20. Helfer BM, Ponomarev V, Patrick S, Blower P, Feitel A, Fruhwirth G, Jackman S, Pereira Mouriès L, Park M, Srinivas M, Stuckey D, Thu M, Van den Hoorn T, Herberts CA, Shingleton W. Options for imaging cellular therapeutics in vivo ; a multi stakeholder perspective. (In preparation).
  21. Sato Y, Bando H, Di Piazza M, Gowing G, Herberts CA, Jackman S, Leoni G, Libertini S, MacLachlan T, McBlane JW, Pereira Mouriès L, Sharpe M, Shingleton W, Surmacz-Cordle B, Yamamoto K, van der Laan JW, Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider. Cytotherapy 2019; 21:1095-1111
  22. Vestergaard HT, Apote LD, Schneider CK, Herberts C. The evolution of nonclinical regulatory science: Advanced therapy medicinal products as a paradigm. Molecular Therapy 2013; 21(9):1644-1648
  23. Harting MT, Jimenez F, Xue H, Fischer UM, Baumgartner J, Dash PK and Cox CS. Intravenous mesenchymal stem cell therapy for traumatic brain injury. Laboratory investigation Journal of Neurosurgery 2014; 110(6):1189-1197
  24. Mount NM, Ward SJ, Kefalas P, Hyllner J. Cell-based therapy technology classifications and translational challenges. Phil. Trans. R. Soc. B 2015; 370:20150017
  25. Mestas J and Hughes CCW. Of Mice and Not Men: Differences between Mouse and Human Immunology J Immunol March 1, 2004; 172(5):2731-2738.
  26. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother 2002; 25(6):500-8.
  27. Balsari A, Marolda R, Gambacorti-Passerini C, Sciorelli G, Tona G, Elisabetta Cosulich E, Donatella Taramelli D, Giuseppe Fossati G, Giorgio Parmiani G, Cascinelli N. Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung - A phase I study. Cancer Immunology Immunotherapy 1986; 21(2): 148-155.
  28. Fibbe WE, Noort WA, Mesenchymal stem cells and hematopoietic stem cell transplantation Annals of the New York Academy of Sciences 2002; 996: 235-244.
  29. Commission Advanced Therapies, Clinical Trial Facilitation Group & European Commission. Q&A on Good laboratory practice (GLP) principles in relation to ATMPs https://www.ema.europa.eu/en/documents/other/good-laboratory-practice-glp-principles-relation-advanced-therapy-medicinal-products-atmps_en.pdf. Accessed May 12, 2020.
  30. Kuroda T, Yasuda S, Sato Y. In vitro detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human induced pluripotent stem cells. Methods Mol Biol. 2014; 1210:183-92.